Welcome to our dedicated page for Becton, Dickinson and Co. news (Ticker: BDX), a resource for investors and traders seeking the latest updates and insights on Becton, Dickinson and Co. stock.
Becton, Dickinson and Company (BD) (NYSE: BDX) is a global medical technology firm committed to advancing healthcare through the development, manufacture, and sale of a broad range of medical supplies, devices, laboratory equipment, and diagnostic products. Established in 1897, BD's mission is to enhance medical discovery, diagnostics, and care delivery. The company's extensive product portfolio serves healthcare institutions, physicians, life science researchers, and others across the globe.
BD is noted for being the world’s largest manufacturer and distributor of medical surgical products such as needles, syringes, and sharps-disposal units. The company also excels in producing pre-filled devices, diagnostic instruments, and reagents. Furthermore, BD offers sophisticated flow cytometry and cell-imaging systems. BD Medical represents nearly half of the company's total business, while BD Life Sciences and BD Interventional contribute 27% and 24% of the 2023 revenue, respectively. Impressively, international revenue accounts for 43% of the company's business.
Recent achievements and projects underscore BD's commitment to innovation and sustainability. The company recently collaborated with health care institutions in Denmark to explore recycling used blood collection tubes, achieving significant environmental advancements without compromising safety or quality.
In a pivotal development, BD announced the global commercial release of new cell sorters, enabling researchers in fields such as cell biology, cancer research, and immunology to gain new insights. The BD FACSDiscover™ S8 Cell Sorters incorporate groundbreaking technologies like BD CellView™ Image Technology and BD SpectralFX™ Technology, significantly enhancing real-time imaging and spectral flow cytometry.
BD also reported robust financial performance for the second quarter of fiscal 2024, highlighting strong operating margins and cash flow. This success led to an optimistic outlook and an increased earnings guidance, demonstrating the company’s resilience and strategic execution.
Further solidifying its market position, BD is set to acquire Edwards Lifesciences' Critical Care product group for $4.2 billion. This acquisition expands BD’s portfolio in smart connected care solutions, leveraging advanced AI algorithms for better patient outcomes and adding significant value to its operations.
With a presence in almost every country and a workforce of over 70,000 employees, BD remains dedicated to advancing the world of health. The company works closely with customers and partners globally to address complex health challenges, enhance clinical outcomes, and expand access to healthcare.
BD (Becton, Dickinson and Company) hosted its Investor Day on Nov. 12, 2021, focusing on its BD 2025 strategy to drive growth through innovation and operational simplification. The company aims for a long-term compound annual revenue growth of 5.5% or more, with double-digit EPS growth and increasing dividends. Key initiatives include organic and inorganic investments, reshaping the innovation pipeline with higher-margin products, and enhancing margins through simplification programs. BD emphasizes disciplined capital deployment to balance growth investments and shareholder returns.
QIAGEN N.V. (NYSE: QGEN) and Becton, Dickinson and Company (NYSE: BDX) have settled a patent infringement lawsuit concerning QIAGEN’s NeuMoDx™ PCR systems. The settlement, resolving all claims, mandates a one-time payment of
BD (Becton, Dickinson and Company) reported strong fiscal 2021 results, with Q4 revenues reaching $5.135 billion, a 7.3% increase year-over-year. Diluted EPS was $0.84, up 133.3%. The company achieved revenue growth across segments, led by BD Medical's 9.2% rise. Despite a decline in COVID-19 diagnostic revenue, BD's outlook for fiscal 2022 anticipates revenue between $19.3 billion and $19.5 billion and adjusted EPS of $12.30 to $12.50, reflecting 5-6% growth. BD also increased its dividend by 4.8% and repurchased 3 million shares for $750 million.
The Board of Directors of BD (Becton, Dickinson and Company) declared a quarterly dividend of $0.87 per share, up 4.8% from the previous quarter, payable on December 31, 2021. This marks the 50th consecutive year of dividend increases, reinforcing BD's status in the S&P 500 Dividend Aristocrats Index. Additionally, the board authorized a share repurchase of up to 10 million shares, adding to the remaining 750,000 shares from a previous program. This strategic move is aimed at enhancing shareholder value, aligned with the company's 2025 strategy.
BD (Becton, Dickinson and Company) has announced a strategic partnership with the Biomedical Advanced Research and Development Authority (BARDA) to develop a suite of COVID-19 combination diagnostic tests. This collaboration will receive initial funding of $24.7 million, potentially extending to $40.3 million. The new tests aim to simultaneously detect multiple respiratory pathogens, enhancing patient management and healthcare resource allocation. BD plans to achieve full FDA clearance for these tests, ensuring their availability even post-COVID-19 emergency.
BD (Becton, Dickinson and Company) will hold a virtual investor day on November 12, 2021, starting at 8 a.m. The event, lasting approximately four hours, will feature presentations from CEO Tom Polen and the executive leadership team, followed by Q&A sessions. A replay and additional materials will be available on BD's investor page after the event. BD is a global leader in medical technology, committed to enhancing healthcare through innovative solutions. For more information, visit bd.com.
BD (Becton, Dickinson and Company) has announced the shipment of its first over-the-counter (OTC) COVID-19 rapid antigen test, utilizing smartphone computer vision technology for result interpretation. Available for $39.99 with promotional pricing at $26.50 on Amazon, the BD Veritor™ test offers digital results in 15 minutes, simplifying at-home testing. It features automated reporting to health agencies and is suitable for individuals aged 14 and older. Authorized under Emergency Use Authorization, the test addresses common at-home testing challenges, including result interpretation and reporting.
BD (Becton, Dickinson and Company) announced the appointment of Dr. Carrie L. Byington to its board of directors, increasing the board to 13 members. Byington is the executive vice president and head of University of California Health, leading a $20 billion academic health system. Her experience includes significant roles at Texas A&M University and the University of Utah. The company views her appointment as timely, aligning with its BD 2025 strategy aimed at innovating in connected care and improving chronic disease outcomes.
On October 18, 2021, BD (Becton, Dickinson and Company) announced its new ESG strategy, Together We Advance, aimed at enhancing its commitment to health, community, and environmental stewardship. This strategy focuses on four pillars: Company Health, Planet Health, Community Health, and Human Health. BD set ambitious 2030 goals, including a 46% reduction in Scope 1 and 2 greenhouse gas emissions and carbon neutrality in direct operations by 2040. The strategy emphasizes climate change, responsible supply chains, and transparency, while aligning with the UN Sustainable Development Goals.
BD (Becton, Dickinson and Company) announced enhanced manufacturing capacity for injection devices to support U.S. vaccination efforts. Completed with the Department of Health and Human Services (HHS), the new lines bolster domestic supply amid ongoing COVID-19 challenges. This follows a $42 million investment from HHS in a previous capital project aimed at expanding BD's operations in Nebraska, underscoring a commitment to both current and future pandemic needs. BD has supplied hundreds of millions of devices, ensuring continuity in healthcare delivery as the flu season approaches.
FAQ
What is the current stock price of Becton, Dickinson and Co. (BDX)?
What is the market cap of Becton, Dickinson and Co. (BDX)?
What does Becton, Dickinson and Company (BD) specialize in?
What are BD's main business segments?
What recent projects has BD undertaken?
How much of BD's revenue comes from international markets?
What significant acquisition has BD announced recently?
How many employees does BD have?
Where can I find more information about BD's financial performance?
What is the significance of the BD FACSDiscover™ S8 Cell Sorters?
Which regulatory body recently issued a safety communication regarding syringes?
What is BD's approach to sustainability?
